We push the boundaries of science and imagination to discover and develop innovative medicines for patients Learn More

The Science of Saving Lives

about-pic-1_1
about-pic-2_1
about-pic-3
about-pic-4_1

About

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for cancers and infectious disease.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.

Senior
Leadership

Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.

Marie-Louise Fjaellskog, M.D., Ph.D.

Chief Medical Officer

John K. Celebi, M.B.A.

President and CEO

Robert Pierce, M.D.

Chief Scientific Officer

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

    GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced today that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the 30Read More

  • Sensei Biotherapeutics Presents Clinical Trial Data Demonstrating SNS-301 Induces Rapid and Robust Antigen-specific Immune Responses at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

    Dose-dependent, ASPH-specific immune responses observed Company to initiate SNS-301 Phase 2 study in multiple solid tumor indications and hematological malignancies in early 2019 GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical companyRead More

  • Sensei Biotherapeutics Reports Results from Phase 1 Clinical Trial of SNS-301, a First-in-Class Cancer Immunotherapy Targeting ASPH, a Novel Tumor-Specific Antigen

    SNS-301 demonstrated a favorable safety profile, improvements in disease parameters, and robust antigen-specific immune responses Clinical results presented in Poster Discussion session at ESMO 2018 Company to initiate Phase 2 study of SNS-301 in multiple solid tumor indications and hematologicalRead More

In the News

Sorting:
Sort Descending
  • Sensei Biotherapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

    GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced today that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the 30Read More

  • Sensei Biotherapeutics Presents Clinical Trial Data Demonstrating SNS-301 Induces Rapid and Robust Antigen-specific Immune Responses at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

    Dose-dependent, ASPH-specific immune responses observed Company to initiate SNS-301 Phase 2 study in multiple solid tumor indications and hematological malignancies in early 2019 GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical companyRead More

  • Sensei Biotherapeutics Reports Results from Phase 1 Clinical Trial of SNS-301, a First-in-Class Cancer Immunotherapy Targeting ASPH, a Novel Tumor-Specific Antigen

    SNS-301 demonstrated a favorable safety profile, improvements in disease parameters, and robust antigen-specific immune responses Clinical results presented in Poster Discussion session at ESMO 2018 Company to initiate Phase 2 study of SNS-301 in multiple solid tumor indications and hematologicalRead More

Signup For Update

sign up for newsletter and get the latest update